Charles River price target lowered to $210 from $230 at Barclays

Barclays lowered the firm’s price target on Charles River to $210 from $230 and keeps an Equal Weight rating on the shares. The firm says that while it was looking for a guide cut, management commentary suggests the large pharma market is deteriorating and the company has limited visibility into when demand is likely to bottom and start to recover. The analyst feels it is too soon to get constructive on the shares.